tiprankstipranks
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine appoints Samir Siddhanti as Chief Business Officer
The FlyNeurocrine appoints Samir Siddhanti as Chief Business Officer
4d ago
NBIX
Neurocrine price target raised to $200 from $175 at Guggenheim
PremiumThe Fly
Neurocrine price target raised to $200 from $175 at Guggenheim
4d ago
NBIX
Neurocrine price target raised to $200 from $175 at Wells Fargo
PremiumThe Fly
Neurocrine price target raised to $200 from $175 at Wells Fargo
9d ago
NBIX
Neurocrine price target raised to $200 from $155 at Truist
PremiumThe Fly
Neurocrine price target raised to $200 from $155 at Truist
12d ago
NBIX
Neurocrine price target raised to $170 from $144 at BMO Capital
PremiumThe Fly
Neurocrine price target raised to $170 from $144 at BMO Capital
12d ago
NBIX
Neurocrine price target raised to $185 from $176 at Wedbush
PremiumThe FlyNeurocrine price target raised to $185 from $176 at Wedbush
12d ago
NBIX
Neurocrine price target raised to $195 from $183 at RBC Capital
Premium
The Fly
Neurocrine price target raised to $195 from $183 at RBC Capital
18d ago
NBIX
Neurocrine initiates Phase 2 study of crinecerfont
Premium
The Fly
Neurocrine initiates Phase 2 study of crinecerfont
24d ago
NBIX
Neurocrine price target raised to $208 from $182 at UBS
PremiumThe Fly
Neurocrine price target raised to $208 from $182 at UBS
26d ago
NBIX
Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors
PremiumCompany Announcements
Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors
1M ago
NBIX
Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged
PremiumRatings
Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged
1M ago
NBIX
Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
PremiumThe Fly
Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
1M ago
NBIX
Neurocrine presents first retrospective case series of Crenessity
PremiumThe FlyNeurocrine presents first retrospective case series of Crenessity
1M ago
NBIX
Neurocrine presents two-year Crenessity data
Premium
The Fly
Neurocrine presents two-year Crenessity data
1M ago
NBIX
Neurocrine reports new post-hoc data from KINECT 4 trial
Premium
The Fly
Neurocrine reports new post-hoc data from KINECT 4 trial
2M ago
NBIX
Neurocrine presents new data showing Improvements with INGREZZA
PremiumThe Fly
Neurocrine presents new data showing Improvements with INGREZZA
2M ago
NBIX
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
PremiumRatings
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
2M ago
NBIX
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
2M ago
KNX
SHW
Neurocrine reinstated with a Buy at Goldman Sachs
PremiumThe Fly
Neurocrine reinstated with a Buy at Goldman Sachs
2M ago
NBIX
Neurocrine price target raised to $183 from $180 at RBC Capital
PremiumThe FlyNeurocrine price target raised to $183 from $180 at RBC Capital
2M ago
NBIX
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
Premium
Company Announcements
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
2M ago
8K
NBIX
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
Premium
The Fly
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
2M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >